title: Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia.
abstract: OBJECTIVE
  We performed a pharmacokinetic evaluation of methotrexate (MTX) in infants with acute lymphoblastic leukemia enrolled on the Pediatric Oncology Group (POG) 9407 Infant Leukemia Study to evaluate the effects of age on MTX pharmacokinetics and pharmacodynamics.
  
  
  METHODS
  A pharmacokinetic database of 61 patients was developed by combining MTX data obtained from 16 patients in a pharmacokinetic sub-study with data obtained for clinical care in other patients enrolled on the POG 9407 protocol. The data were analyzed for the first dose of MTX given to patients in induction/intensification therapy. Patients received MTX (4 g/m2) over 24 h at week 4 of therapy. Toxicity data were also reviewed to evaluate the incidence of common MTX toxicities during the first 6 weeks of therapy (the induction/intensification phase).
  
  
  RESULTS
  Steady-state clearance (mean+/-standard deviation) for infants aged 0-6 months was 89+/-32 ml/min/m2 compared to 111+/-40 for infants aged 7-12 months (P=0.030). In the subgroup of infants aged 0-3 months the mean steady-state clearance was 84+/-30 ml/min/m2 (P=0.026 vs. the 7-12-month group). The incidence of renal toxicity (all grades) during induction/intensification therapy was 23% in the 0-3 months age group compared to 0% (for n=27) in the group 7-12 months of age (P=0.029). There were no significant differences in hepatoxicity or mucous membrane toxicity between age groups.
  
  
  CONCLUSIONS
  A modest difference in steady-state MTX clearance is observed between younger infants (0-6 months) and older infants (7-12 months). Very young infants (0-3 months) also experienced a slightly higher incidence of renal toxicity during induction/intensification therapy. Steady-state clearance for the older infants is similar to values reported for children in other studies.
authors.affiliation: Texas Children's Cancer Center, Baylor College of Medicine, 6621 Fannin St MC, Houston, TX 77030-2399, USA.
authors.forename: Patrick A
authors.initials: PA
authors.lastname: Thompson
authors.forename: Daryl J
authors.initials: DJ
authors.lastname: Murry
authors.forename: Gary L
authors.initials: GL
authors.lastname: Rosner
authors.forename: Simon
authors.initials: S
authors.lastname: Lunagomez
authors.forename: Susan M
authors.initials: SM
authors.lastname: Blaney
authors.forename: Stacey L
authors.initials: SL
authors.lastname: Berg
authors.forename: Bruce M
authors.initials: BM
authors.lastname: Camitta
authors.forename: ZoAnn E
authors.initials: ZE
authors.lastname: Dreyer
authors.forename: Lisa R
authors.initials: LR
authors.lastname: Bomgaars
mesh_terms: D000367:Age Factors; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008727:Methotrexate / Q000009:adverse effects / Q000493:pharmacokinetics*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D008727:Methotrexate